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 Diabetic nephropathy (DN) is the single 
major cause of end-stage kidney disease in 
the industrialized world. DN typically 
develops late in the course of diabetes, in 
part as a consequence of persistent meta-
bolic sequelae of hyperglycemia. The 
delayed onset, heterogeneous progression, 
and complex etiology of DN have made 
identification of bona fide therapeutic 
 targets for intervention challenging. 
 Angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers, the 
 current standard of care, have been shown 
to signifi cantly slow the progression of the 
disease above and beyond their antihyper-
tensive eff ects, yet there remains a dire need 
for the development of novel  ‘ add-on ’ 
 therapies to protect patients from progres-
sion to end-stage renal disease and dialysis. 
 Th e initial diagnosis of DN is based on 
the detection of microalbuminuria. Th e 
exact molecular mechanisms responsible 
for the development of albuminuria are 
not known, although it has been proposed 
that among the diverse metabolic derange-
ments associated with diabetes, increased 
reactive oxygen species, protein modifi ca-
tion by advanced glycation end products, 
uncoupling of endothelial nitric oxide 
synthase, and upregulation of numerous 
cytokines and growth factors contribute 
to this process. 1 Nicholas  et al. 2 (this issue) 
propose that osteopontin (OPN) is a crit-
ical component participating in the patho-
genesis of albuminuria and mesangial 
expansion in DN. Th ey also propose that 
the protective renal eff ects of thiazolidin-
ediones (TZDs), ligands of peroxisome 
proliferator-activated receptor-  (PPAR  ), 
in DN are due to the suppression of OPN 
production. Th e authors present (1) exten-
sive experimental evidence from a murine 
model of streptozotocin-induced diabetes 
in which they compare the protective 
effects of insulin versus TZDs on the 
expression of glomerular OPN and albu-
minuria; (2) evidence for renal protection, 
including reduced albuminuria and 
glomerular pathology, in models of both 
type I and type II DN in OPN knockout 
mice; and (3)  in vitro data demonstrating 
the eff ects of TZDs on OPN expression 
and the eff ects of recombinant OPN on 
transforming growth factor-  expression 
in cultured mouse mesangial cells. 
 Th e mechanism of these protective eff ects 
is unclear. OPN, also known as secreted 
phosphoprotein 1 (Spp1), is a complex 
secreted glycoprotein that contains several 
diff erent domains, one of which is an RGD 
binding domain involved in the binding of 
integrins such as   v  3 , the vitronectin recep-
tor. 3 Th is binding is believed to be involved 
in the facilitation of cell adhesion and migra-
tion ( Figure 1 ) . Th e protein structure of 
OPN has been shown to undergo proteolytic 
processing at several sites by thrombin and 
matrix metalloproteases, generating frag-
ments that either suppress or enhance 
cellular adhesion and migration. Outside of 
a role for cellular adhesion and migration, 
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OPN has also been shown to play a promi-
nent role in inflammation, promoting 
macrophage infi ltration and retention in tis-
sues, macrophage activation / activity, and 
secretion of cytokines ( Figure 1 ). OPN-null 
mice have been shown to have deficits 
in macrophage function. 4 OPN has also 
been shown to aff ect lymphocyte adhesion 
and migration as well as costimulation. Th e 
contribution of these various pathways 
to the eff ects reported by Nicholas  et al. 2 
remains to be fully elucidated. 
 Th e study by Nicholas  et al. 2 confi rms a 
recent report by Lorenzen and colleagues, 5 
who used a similar approach to demon-
strate a role for OPN in the development 
of albuminuria. Th ey demonstrated that 
OPN-null C57BL6 / Ins2 Akita diabetic mice 
exhibit dramatically reduced albuminuria, 
compared with wild-type C57BL6 /
 Ins2 Akita diabetic mice. Interestingly, their 
study focused on the podocyte as a cell in 
which OPN exerts its detrimental eff ect 
through activation of the nuclear factor-
  B pathway and increased expression of 
urokinase plasminogen activator and 
matrix metalloproteases, leading to 
increased podocyte motility. In contrast, 
Nicholas and colleagues 2 focused on the 
mesangial cell, in which OPN was shown to 
upregulate transforming growth factor-  , 
ERK / MAPK / JNK signaling, and matrix 
deposition. Th ey propose that direct actions 
of OPN on mesangial cells represent impor-
tant mechanisms by which OPN contri-
butes to DN. 
 Th e OPN-null mouse has been used in 
other models of renal disease, including 
obstructive uropathy 6 and angiotensin II 
infusion, 7 providing further support for 
a role for OPN in the development of 
albuminuria and renal fi brosis in kidney 
disease. Studies examining disease in a 
genetic null background represent a good 
starting point for assessing the role a gene 
might play in a disease process, but this 
approach does come with some caveats. 
Th e analysis tests the role a gene plays in 
the initiation of the disease, but not nec-
essarily in disease progression. In the 
clinic, only patients with established dis-
ease are typically treated, and therapy 
must be able to slow its progression. Th us, 
analysis of OPN neutralization aft er DN 
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has been established in an animal model 
would provide an important alternative 
method to determine the importance of 
OPN as a therapeutic target for DN. 
Although OPN-neutralizing anti bodies 
have been shown to reduce tubulo-
interstitial macrophage infi ltration in a 
rat model of glomerulonephritis, 8 such 
 studies, to our knowledge, are lacking in 
animal models of DN. 
 Finally, Nicholas and colleagues 2 sug-
gest that the eff ect of TZDs on DN occurs 
through the suppression of OPN. Th ey 
present evidence showing that glomeru-
lar OPN expression in  db / db mice is 
downregulated to a greater extent by 
TZDs (rosi glitazone and pioglitazone) 
than by insulin. Th ey further show that 
angiotensin II upregulates OPN in mouse 
mesangial cells, and that TZDs down-
regulate OPN expression in these cells to 
a greater extent than insulin. Oyama  et 
al. 9 have shown that PPAR  ligand inhib-
its OPN gene expression through inter-
ference with the binding of nuclear 
factors to A / T-rich sequences in THP-1 
cells, thus strengthening this idea. 
However, TZDs are known to exert 
other effects on cells, including anti-
 infl ammatory eff ects that could poten-
tially contribute to their eff ects on DN as 
well. Nicholas  et al. 2 go on to suggest that 
clinical studies examining the eff ects of 
TZDs in both type I and type II diabetes 
are supported by their data. Indeed, there 
are currently several clinical trials inves-
tigating TZDs in DN, but whether OPN 
is a critical contributor to the disease 
process or simply a sign of more severe 
disease will not be addressed by these 
results. In conclusion, while OPN may 
represent a therapeutic target for the 
treatment of DN, the question of how to 
best validate this possibility, and whether 
there may be other off setting issues asso-
ciated with the neutralization of OPN, 
will most likely weigh signifi cantly on the 
viability of such a therapy. 
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 Figure 1  |  Interplay of pathological mechanisms due to OPN production and action. Increased angiotensin II (Ang II) stimulates the production of 
osteopontin (OPN) in the glomerulus, including in mesangial cells. Increased OPN modifies podocyte biology, contributing to albuminuria as well as 
 promoting the production of transforming growth factor-  (TGF-  ) and monocyte chemoattractant protein-1 (MCP-1) from mesangial cells. TGF-  stimulates 
increased mesangial matrix production, and MCP-1 recruits macrophages through chemotaxis. OPN stimulates cytokine production from macrophages. 
AT1R, angiotensin II type I receptor; ECM, extracellular matrix; IFN-  , interferon-  ; IL-12, interleukin-12; TGF-  RII, transforming growth factor beta receptor two. 
